Marinus Pharmaceuticals, Inc.

Historical 13F Holders

Symbol
MRNS
CUSIP
56854Q200
All holders as of
Q4 2024
Type
Equity
Class
COM NEW
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 56854Q200 since 12/18/2024, newest first.

Filer % of Class Filed
Beryl Capital Management LLC 13G/A Amendment 1
0% 5/15/2025
Event 3/31/2025
Morgan Stanley 13G/A Amendment 1
0% 3/6/2025
Event 2/28/2025
Tang Capital Partners LP 13G/A Amendment 1
3.0% 2/14/2025
Event 12/31/2024
Panacea Innovation Ltd 13G/A Amendment 1
0% 2/14/2025
Event 12/31/2024
Sofinnova Investments, Inc. 13G/A Amendment 1
0% 2/12/2025
Event 12/31/2024
Suvretta Capital Management, LLC 13G
5.5% 2/11/2025
Event 2/7/2025
Suvretta Capital Management, LLC 13G/A Amendment 4
3.8% 2/11/2025
Event 12/31/2024
Franklin Resources, Inc. 13G/A Amendment 2
0% 2/11/2025
Event 12/31/2024
Morgan Stanley 13G
6.0% 2/4/2025
Event 12/31/2024
Vanguard Group Inc 13G/A Amendment 1 4.7% 1/31/2025
Event 12/31/2024
Beryl Capital Management LLC 13G
9.9% 1/7/2025
Event 12/30/2024
Franklin Resources, Inc. 13G/A Amendment 1
8.6% 10/31/2024
Event 9/30/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2024 Q4 57 29.6 M $15.8 M
2024 Q3 84 41.5 M $73.8 M
2024 Q2 98 43.5 M $50.9 M
2024 Q1 139 54.7 M $494 M
2023 Q4 126 54.5 M $593 M
2023 Q3 122 51.1 M $411 M
2023 Q2 121 44.7 M $485 M
2023 Q1 100 41.1 M $284 M
2022 Q4 87 40.6 M $166 M
2022 Q3 79 28.9 M $187 M
2022 Q2 79 28.8 M $141 M
2022 Q1 97 30.0 M $281 M
2021 Q4 86 30.0 M $357 M
2021 Q3 91 31.8 M $362 M
2021 Q2 91 31.5 M $563 M
2021 Q1 98 31.9 M $493 M
2020 Q4 101 29.8 M $363 M
2020 Q3 85 18.6 M $239 M